Rongchang Biotech: Currently, the overseas clinical trials of RC48 are progressing as planned.

Rongchang Biological said at the performance briefing that the company reached a global exclusive license agreement with Seattle Genetics in 2021. The company authorized the global development and commercialization rights for Vedolizumab outside of the Rongchang Biological region. Currently, the overseas clinical trials of RC48 are being pushed forward by Pfizer as planned. In the internationalization process, the main challenges faced include the differences in regulatory environments in different countries and regions, the complexity of market access policies, and the dynamic changes in the competitive environment. The company is actively collaborating closely with Pfizer, providing necessary support and data to assist in clinical development and reporting work in overseas markets.